The clinical decision to give primaquine as radical treatment for P. vivax malaria and mixed infections in this vulnerable group without G6PD testing should be made with great caution, particularly in areas with a higher prevalence of G6PD deficiency. The gene discussed is G6PD; the disease is G6PD deficiency.